Karyopharm Therapeutics Inc.
KPTI
$5.46
$0.101.87%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.98% | -5.77% | 1.19% | -0.55% | 1.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.98% | -5.77% | 1.19% | -0.55% | 1.77% |
| Cost of Revenue | -136.98% | -108.93% | -46.55% | 21.55% | 228.27% |
| Gross Profit | 12.90% | 6.74% | 4.29% | -1.32% | -17.11% |
| SG&A Expenses | -7.83% | -9.39% | -9.78% | -12.47% | -14.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.11% | -8.73% | -4.32% | -3.95% | -0.20% |
| Operating Income | 17.33% | 12.02% | 10.17% | 7.79% | 2.43% |
| Income Before Tax | -42.94% | -37.86% | 57.19% | 46.51% | 37.50% |
| Income Tax Expenses | -99.66% | -101.79% | -93.53% | -82.35% | 11.28% |
| Earnings from Continuing Operations | -42.46% | -37.43% | 57.27% | 46.60% | 37.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.46% | -37.43% | 57.27% | 46.60% | 37.41% |
| EBIT | 17.33% | 12.02% | 10.17% | 7.79% | 2.43% |
| EBITDA | 17.39% | 12.04% | 10.20% | 7.68% | 2.26% |
| EPS Basic | -30.34% | -23.13% | 56.42% | 50.04% | 43.34% |
| Normalized Basic EPS | 12.80% | 16.05% | 32.55% | 20.24% | 17.59% |
| EPS Diluted | 11.02% | 14.39% | 28.08% | 22.29% | 17.26% |
| Normalized Diluted EPS | 9.79% | 13.27% | 35.47% | 23.22% | 20.34% |
| Average Basic Shares Outstanding | 7.54% | 8.93% | 8.75% | 6.69% | 10.26% |
| Average Diluted Shares Outstanding | 0.50% | 1.64% | 16.02% | 14.00% | 17.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |